469 related articles for article (PubMed ID: 19488082)
21. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy.
Salzman C; Jeste DV; Meyer RE; Cohen-Mansfield J; Cummings J; Grossberg GT; Jarvik L; Kraemer HC; Lebowitz BD; Maslow K; Pollock BG; Raskind M; Schultz SK; Wang P; Zito JM; Zubenko GS
J Clin Psychiatry; 2008 Jun; 69(6):889-98. PubMed ID: 18494535
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression.
Zahodne LB; Ornstein K; Cosentino S; Devanand DP; Stern Y
Am J Geriatr Psychiatry; 2015 Feb; 23(2):130-40. PubMed ID: 23871118
[TBL] [Abstract][Full Text] [Related]
23. Non-pharmacological interventions for agitation/aggressive behaviour in patients with dementia: a randomized controlled crossover trial.
Dimitriou TD; Verykouki E; Papatriantafyllou J; Konsta A; Kazis D; Tsolaki M
Funct Neurol; 2018; 33(3):143-147. PubMed ID: 30457967
[TBL] [Abstract][Full Text] [Related]
24. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
25. An update on the advancements in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Antonsdottir IM
Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
[TBL] [Abstract][Full Text] [Related]
26. Electroconvulsive therapy (ECT) for treating agitation in dementia (major neurocognitive disorder) - a promising option.
Glass OM; Forester BP; Hermida AP
Int Psychogeriatr; 2017 May; 29(5):717-726. PubMed ID: 28095946
[TBL] [Abstract][Full Text] [Related]
27. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality.
Ballard C; Creese B; Corbett A; Aarsland D
Expert Opin Drug Saf; 2011 Jan; 10(1):35-43. PubMed ID: 20684745
[TBL] [Abstract][Full Text] [Related]
28. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
[TBL] [Abstract][Full Text] [Related]
29. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia.
Paunescu H; Dima L; Ghita I; Coman L; Ifteni PI; Fulga I; Coman OA
Am J Ther; 2020; 27(3):e249-e269. PubMed ID: 32118591
[TBL] [Abstract][Full Text] [Related]
30. Dementia-related agitation: a review of non-pharmacological interventions and analysis of risks and benefits of pharmacotherapy.
Ijaopo EO
Transl Psychiatry; 2017 Oct; 7(10):e1250. PubMed ID: 29087372
[TBL] [Abstract][Full Text] [Related]
31. Risperidone in the management of agitation and aggression associated with psychiatric disorders.
De Deyn PP; Buitelaar J
Eur Psychiatry; 2006 Jan; 21(1):21-8. PubMed ID: 16414250
[TBL] [Abstract][Full Text] [Related]
32. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.
Cummings JL; Schneider E; Tariot PN; Graham SM;
Neurology; 2006 Jul; 67(1):57-63. PubMed ID: 16832078
[TBL] [Abstract][Full Text] [Related]
33. Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
Oliveira LF; Camargos EF; Martini LLL; Machado FV; Novaes MRCG
Psychiatry Res; 2021 Jan; 295():113591. PubMed ID: 33271491
[TBL] [Abstract][Full Text] [Related]
34. Psychotic symptoms, aggression and restlessness in dementia.
Ballard C; Gray A; Ayre G
Rev Neurol (Paris); 1999; 155 Suppl 4():S44-52. PubMed ID: 10637938
[TBL] [Abstract][Full Text] [Related]
35. A descriptive analysis of pharmacological management of aggression and/or agitation in patients with traumatic brain injury in a Southwest Virginia inpatient population.
Rahmani E; Lemelle T; Sharp H; Smarbafzadeh E; Kablinger A
J Clin Pharm Ther; 2022 Dec; 47(12):2083-2090. PubMed ID: 36543254
[TBL] [Abstract][Full Text] [Related]
36. The treatment of behavioral disturbances and psychosis associated with dementia.
Lochhead JD; Nelson MA; Maguire GA
Psychiatr Pol; 2016; 50(2):311-22. PubMed ID: 27288676
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia.
Tariot PN; Erb R; Podgorski CA; Cox C; Patel S; Jakimovich L; Irvine C
Am J Psychiatry; 1998 Jan; 155(1):54-61. PubMed ID: 9433339
[TBL] [Abstract][Full Text] [Related]
39. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication.
Forester B; Vanelli M; Hyde J; Perez R; Ahokpossi C; Sribney W; Adkison L
Am J Geriatr Pharmacother; 2007 Sep; 5(3):209-17. PubMed ID: 17996660
[TBL] [Abstract][Full Text] [Related]
40. The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease.
Creese B; Da Silva MV; Johar I; Ballard C
Expert Rev Neurother; 2018 Jun; 18(6):461-467. PubMed ID: 29764230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
